BioSpace News Archive

The unprecedented COVID-19 crisis has unleashed global emotional trauma that is rapidly evolving into a mental health pandemic within the pandemic.

HealthLynked Corp (HLYK), a global healthcare network focused on care management of its members and a provider of healthcare technologies that connect doctors, patients and medical data, today announced that it closed its acquisition of Cura Health Management, LLC (" CHM ") and its wholly owned subsidiary ACO Health Partners, LLC

A new study published in the International Journal of Eating Disorders finds that eating disorder patients who identify as LGBT have more severe eating disorder symptoms, higher rates of trauma history, and longer delays between diagnosis and treatment than heterosexual, cisgender patients.

Used by more than 200 health systems for telehealth, platform goes beyond standard video conferencing to facilitate stethoscope audio, ECG live-streaming and FDA-cleared identification of atrial fibrillation ( AFib) and heart murmurs Patients can video chat with their providers and navigate self-operated stethoscope exams OAKLAND, Calif.--( BUSINESS WIRE )-- Eko today announced Eko Telehealth, the first and only AI-powered telehealth platfor

Only PARP inhibitor to improve overall survival vs enzalutamide or abiraterone in the biomarker-based subset of prostate cancer patients with BRCA1/2 or ATM mutations

Biodesix, Inc., a leading diagnostic company in lung disease, announced that it has partnered with Boulder Community Health, a community owned-and-operated not-for-profit health system, to offer expanded COVID-19 testing in the greater Boulder, CO area.

Aldeyra Therapeutics, Inc. announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19, and provided an update on ADX-629, a novel investigational RASP inhibitor in development for COVID-19 and other inflammatory diseases.

Data from multiple studies, including results in the outpatient administration setting and using machine learning technology, evaluating potential of CAR T liso-cel in relapsed and refractory large b-cell lymphoma

McKesson Corporation reported results for the fourth quarter and fiscal year ended March 31, 2020.

LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing (NGS) partner